Epigenomics in cancer management by Costa, Fabricio F
© 2010 Costa, publisher and licensee Dove Medical Press Ltd. This is an Open Access article  
which permits unrestricted noncommercial use, provided the original work is properly cited.
Cancer Management and Research 2010:2 255–265
Cancer Management and Research Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
255
Review
open access to scientific and medical research
Open Access Full Text Article
DOI: 10.2147/CMR.S7280
epigenomics in cancer management
Fabricio F Costa
Cancer Biology and epigenomics 
Program, Children’s Memorial 
Research Center and Northwestern 
University’s Feinberg School of 
Medicine, 2430 N. Halsted St,  
Box 220, Chicago, iL, USA
Correspondence: Fabricio F Costa 
Cancer Biology and epigenomics Program, 
Children’s Memorial Research Center 
and Northwestern University’s Feinberg 
School of Medicine, 2430 N. Halsted St, 
Box 220, Chicago, iL, USA 
Tel +1 773 880 4000 ext. 57312 
Fax +1 773 755 6551 
email fcosta@childrensmemorial.org
Abstract: The identification of all epigenetic modifications implicated in gene expression is the 
next step for a better understanding of human biology in both normal and pathological states. This 
field is referred to as epigenomics, and it is defined as epigenetic changes (ie, DNA methylation, 
histone modifications and regulation by noncoding RNAs such as microRNAs) on a genomic scale 
rather than a single gene. Epigenetics modulate the structure of the chromatin, thereby affecting the 
transcription of genes in the genome. Different studies have already identified changes in epigenetic 
modifications in a few genes in specific pathways in cancers. Based on these epigenetic changes, 
drugs against different types of tumors were developed, which mainly target epimutations in the 
genome. Examples include DNA methylation inhibitors, histone modification inhibitors, and small 
molecules that target chromatin-remodeling proteins. However, these drugs are not specific, and 
side effects are a major problem; therefore, new DNA sequencing technologies combined with 
epigenomic tools have the potential to identify novel biomarkers and better molecular targets to 
treat cancers. The purpose of this review is to discuss current and emerging epigenomic tools and 
to address how these new technologies may impact the future of cancer management.
Keywords: genomics, epigenomics, epigenetics, DNA methylation, histone modifications, new 
technologies, cancer management
Introduction
Sequencing the human genome marked not the end of the field of genomics, but its 
beginning. Scientists now stand in a unique position in the history of medicine to 
define human disease, armed with the technological advancements and the data that has 
resulted from the Human Genome Project.1,2 Using this information, some progress has 
already been made toward launching individualized and personalized medicine, espe-
cially for certain types of cancer. For example, the launch of different types of genetic 
tests to predict disease (preventive medicine) and the development of the drug imatinib 
(Gleevec) for blood tumors3 were major breakthroughs. In addition, biomarkers that 
are able to subgroup tumors based on aggressivity, thus aiding in clinical decisions, 
were also identified.4 A precise molecular characterization of human cancers will allow 
a better understanding of the basis for disease susceptibility and environmental influ-
ence, better diagnosis and prognosis, and the refinement of individualized treatment 
for optimal therapeutic efficacy.
Genomes from various individuals have already been sequenced,5,6 allowing genomic 
comparisons. Projects such as the HapMap7 that identified variations in the human 
genome, and ENCODE8 that is analyzing the functional elements in the genome, are 
helping in the understanding of complex disease phenotypes. Such projects have the Cancer Management and Research 2010:2 submit your manuscript | www.dovepress.com
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potential to help elucidate the information encoded by human 
genomes and aid in the treatment of diseases such as cancer.
One of the main issues in genomic science is understanding 
how gene expression is regulated. To understand the 
mechanisms that are implicated in gene regulation, the genes 
that are expressed in each cell type of the body and how 
changes in their expression will impact in the development of 
diseases represent major challenges. In addition, environmen-
tal factors such as the exposure to chemical compounds during 
life, smoking, and nutrition can clearly affect and change the 
expression of genes.9 Thus, in the post-genomic era, studies 
of how human genes are regulated and the mechanisms that 
are implicated in this process are of major importance for our 
understanding of normal processes and diseased states.
The information beyond the genome sequence was 
recently coined as the epigenome.10 The epigenome is defined 
as the group of modifications that can occur at a genomic 
level that will not change the sequence of the bases of the 
DNA but can change the DNA conformation and, as a con-
sequence, change the expression of genes. Epigenetics is the 
study of these modifications in the DNA.11 The following 
are the main epigenetic modifications that occur in the DNA 
molecule: 1) binding of different proteins to the DNA such as 
histones and methyl-binding proteins, 2) addition of chemical 
groups in the bases of the DNA such as methyl (CH3), and 
3) microRNAs and other noncoding RNAs that can regulate 
the expression of genes through various mechanisms.
While epigenetics has garnered more attention, it is not 
a new field, and studies dating from the 1980s have shown 
the promise of using drugs that affect these mechanisms 
to treat diseases, especially cancers.12,13 In the last decade, 
we have been facing an overwhelming increase in drugs 
affecting epigenetic mechanisms that have been developed 
to treat different types of cancer (see Table 1 and Figure 1). 
Examples are a growing number of DNA methylation inhibi-
tors, histone modification inhibitors, and small molecules 
that target chromatin-remodeling proteins. 5-Azacytidine 
was the first inhibitor of an enzyme implicated in epige-
netic modifications described.14 This drug inhibits the DNA 
methyltransferase (DNMT) enzyme that is responsible for 
adding methyl groups to cytosines located in both DNA and 
RNA molecules. Another example of a DNMT inhibitor is 
Table 1 Drugs developed using epigenetics and epigenomics tools
Drug Mode of action Types of cancer References
Belinostat1 Histone deacetylase inhibitor Hematological malignancies and 
solid tumors
71,72
Dacogen1 or vidaza2  
and decitabine2
DNA methyltransferase inhibitors  
(5-azacytidine and 5-aza-2′-deoxycytidine)
Myelodysplastic syndrome and  
hematological malignancies. Tests  
have already started in solid tumors
38,73,74
DZNep1 (Deazaneplanocin A) Histone methyltransferase inhibitor Acute myeloid leukemia 75
entinostat1 (MS-275) Benzamide histone acetylase inhibitor Blood and lung tumors 72,76
Panobinostat1 (LBH589) inhibitor of the enzyme histone deacetylase  
in a mechanism leading to apoptosis  
of malignant cells via multiple pathways
Cutaneous T-cell lymphoma, chronic  
myelogenous leukemia, myelodysplastic  
syndromes, breast cancer, pancreatic 
cancer, and prostate cancer
77–79
RG1083 Small molecule specifically designed to bind  
and inhibit the active domain of the DNA 
methyltransferase 1 enzyme
Different types of cancer 80
CP-42003 Molecule conjugated to a lipid chain linked  
to azacytidine that accelerates cellular uptake
Different types of cancer 81
S1103 Modified and less toxic version of 5-aza-2′- 
deoxycytidine; DNA methyltransferase inhibitor
Different types of cancer 82
Romidepsin1 Natural product that inhibits histone  
deacetylases and causes  
cancer cell apoptosis
Under clinical trials to cutaneous T-cell  
lymphoma, peripheral T-cell lymphoma, 
and a variety of other cancers
83
valproic Acid2 (Depakote) Histone deacetylase inhibitor Multiple myeloma, gliomas, and melanoma 84
vorinostat2 (Solinza) Histone deacetylase inhibitor Lymphomas, glioblastoma 
multiforme, and other solid tumors
72,85
Pyroxamide2 (SAHA) Histone deacetylase inhibitor Hematological malignancies, prostate  
cancer, bladder cancer, and neuroblastoma
86
Sirtinol and Salermide3 SiRT1 protein inhibitors Different types of cancer 43,87
Notes: There might be other examples of epigenetic-based drugs under development and/or in clinical trials that were not described here. 1in clinical trials; 2Approved by 
the FDA; 3Under development.Cancer Management and Research 2010:2 submit your manuscript | www.dovepress.com
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5-aza-2′-deoxycytidine, which is incorporated just in the 
DNA molecule. The DNA methyltransferase covalently binds 
to these nucleotide analogs, and this sequestration affects 
its normal function. These compounds can also affect the 
way proteins implicated in cell regulation are able to bind 
to the DNA/RNA substrates. 5-Azacytidine was first tested 
in myelodysplastic syndrome and leukemia, and it showed 
promising results in patients with both diseases.15,16 Since 
5-azacytydine and other epigenetic drugs are not very spe-
cific, side effects are a major problem. A challenge faced 
by researchers in this field is two-fold: design more specific 
drugs and drugs that have fewer side effects since they have 
a global effect in the epigenome of the cells. To overcome 
this issue, new DNA sequencing technologies (second and 
third generation) combined with epigenomic tools have 
emerged. It is becoming clear that these technologies may 
facilitate the identification of better molecular targets for 
drug development and biomarker identification for cancer 
management. In that regard, the main purpose of this review 
is to discuss the emergence of epigenomic tools derived from 
new DNA sequencing technologies and how they may affect 
the management of cancer in the future.
Cancer genomics – now and then
Genomics is defined as the study of entire genomes of 
organisms, including extrachromosomal DNA such as the 
mitochondrial genetic material. This field includes intensive 
efforts to determine the entire DNA sequence of organisms, 
using fine-scale genetic mapping and DNA sequencing with 
current and emerging technologies. In contrast, investigating 
the roles of single genes is a primary focus of genetics. Single 
gene research does not fall into the definition of genomics 
unless the aim is to verify the effect that a gene may have on 
the entire genome’s networks and pathways. Genomics has 
been the main focus in molecular biology, especially after 
the completion of the sequencing of genomes from several 
organisms. Genomics tools have already helped in the under-
standing of several aspects of the genome of cancer cells 
when compared to normal controls. One important example 
is the identification of the gene HER2/neu (ErbB-2), which is 
an oncogene mapped to human chromosome 17 that is over-
expressed, or amplified, in ∼30% of breast cancer tumors.17 
Identification of this molecular characteristic culminated 
in the development of the drug trastuzumab (Herceptin).18 
Breast cancer patients that are HER2/neu (ErbB-2) positive 
have increased survival rates when treated with this drug.18
One question that has recently emerged after the sequenc-
ing of entire human genomes and comparisons between them 
is ‘What have we learned from sequencing human genomes?’ 
It is clear that important advances were generated after the 
sequencing of the first human genome a decade ago. These 
advancements were mainly applied to basic science such as 
improvements in DNA sequencing technologies, a decrease 
in the cost for sequencing the DNA molecule, and also the 
development of new methods to analyze molecular changes 
in diseases; for example, there was an increase in the number 
of predictive and prognostic genetic tests for cancers and 
other diseases. In contrast, for applied medicine and patients, 
there have been a disappointingly small number of drugs 
and therapies that were discovered and developed using 
genomics tools. Hence, we have learned that the sequence 
of human genomes is just a starting point to generate and 
accumulate the basic information needed for more complex 
and deeper analyses.
Recently, cancer genomes were sequenced and com-
pared with normal cells for leukemia, breast, lung, and 
other tumor types, using second-generation DNA sequenc-
ing technologies.19–25 The purpose was to identify mutations 
that could give rise to new biomarkers and new therapies for 
these types of cancers. In addition, the 1000 Genome Project 
was recently launched26 with the objective of sequencing 
the genome of thousands of individuals in a small period of 
time. In parallel, companies are starting to provide whole 
genome sequencing services, with the aim of understanding 
the individual’s susceptibility for diseases, including different 
cancers.27 As a result, a large number of individuals will have 
their genomes sequenced in the years to come. But is this 
enough to understand how the human cell machinery works 
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Figure 1 epigenomics and cancer therapy. Schematic representation of the three 
main  epigenomic/epigenetic  components  that  are  implicated  in  gene  expression 
control in human cells (blue). Some drugs that are in current use, under development, 
and in clinical trials for each epigenetic mechanism of gene regulation are shown in 
green. The drugs presented here are just a representative list for each mechanism, and 
some drugs under development and in clinical trials at the moment are not shown.Cancer Management and Research 2010:2 submit your manuscript | www.dovepress.com
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and to determine how cancer or any other disease arises? 
It is likely that the technology will be beneficial to genomic 
science in the future by paving new ways of approaching 
diseases, especially cancers. Even though the genomic 
information will be of importance to identify mutations and 
other chromosomal abnormalities (ie, insertions or deletions 
in the genomic DNA of diseased cells), more studies will be 
necessary to completely understand human genomes. In this 
regard, the big challenge will be to identify and catalog all the 
genes that are present in normal cells and their defects (muta-
tions, deletions, insertions, amplifications, fusion proteins, 
etc) in tumors. There is growing evidence that epigenomics 
will contribute to this understanding, and in the following 
sections, I will discuss drugs based on epigenetic mechanisms 
that are currently in use, in clinical trials, and under develop-
ment. Furthermore, I will also discuss how this field could 
aid in the development of better therapies for cancer and in 
the identification of new biomarkers.
Epigenomics and new therapies
Epigenomics is becoming more important as the technologies 
for genome-wide epigenetic modification analyses improve. 
The best-known epigenetic marker is DNA methylation, and 
some genes are already described with this epigenetic change 
in different tumor types.28 DNA methylation occurs in normal 
cells mainly in regions that are intergenic, and loss of methyla-
tion (hypomethylation) in these areas was first reported in the 
1980s.29 Loss of DNA methylation or global hypomethylation 
is an early event in cancer, and when it occurs in repetitive 
regions of the genome, the consequences can be chromosomal 
instability, as previously described.30 On the other hand, gain of 
DNA methylation (hypermethylation) in the promoter region 
of different genes can lead to a decrease in the expression of 
this gene (also known as downregulation) and can be one of 
the causes for cancer development.31 It is hypothesized that 
DNA methylation may affect gene expression by blocking 
transcription after methyl-binding and other proteins form a 
complex that blocks the access for transcription factors to the 
gene promoter.32 However, there are other models suggesting 
that DNA methylation is the consequence instead of the cause 
of gene inactivation.33 In this case, defects in the transcription 
factors such as mutations will leave promoter regions ‘opened’ 
and more susceptible to the action of the DNMTs.33 Conse-
quently, these regions of the DNA will be methylated.33
Different genes are already described as hypermethylated 
in the initiation and progression of several types of tumors.34 
The enzymes responsible for the control of DNA methylation 
in eukaryotic cells are the DNMTs.35 There are three 
enzymes already described: DNMTs 1, 2, and 3. However, 
DNMT1 may be the most important, especially in diseases 
such as cancer.36 Different types of drugs that target DNMTs 
have already been developed. The idea behind using a drug 
that blocks the enzymes that control DNA methylation is that 
in cancer, there is an increase in their activity.37 Drugs that 
block DNMTs include 5-azacytidine, 5-aza-2′-deoxycytidine, 
small molecule inhibitors, and others (see Table 1 for more 
details). 5-Azacytidine (Vidaza) was approved by the Food 
and Drug Administration (FDA) since it increased the sur-
vival of patients with myelodysplastic syndrome, and many 
patients on Vidaza became transfusion independent, showing 
the potential for this type of therapy.38
Histone marks were recently described as an important 
epigenetic modification to control gene expression in normal 
cells.39 Histone modifications, such as methylation, acetylation, 
ADP-ribosylation, ubiquitination, phosphorylation, and others, 
to histone tails alter chromatin structure. However, a complete 
understanding of the precise molecular mechanisms by which 
these alterations to histone tails influence DNA-histone interac-
tions remains elusive. There are two main hypothesis on how 
histone modifications can affect chromosome function: 1) they 
may alter the electrostatic charge of the histone, resulting in 
a structural change in histones or their binding to DNA; or 
2) these modifications are binding sites for protein recognition 
motifs, such as the bromodomains or chromodomains, that rec-
ognize acetylated lysines or methylated lysines, respectively.40 
The existence of these modifications and recognition motifs led 
to the ‘histone code’ hypothesis proposed by Strahl and Allis.41 
Overall, post-translational modifications of histones create an 
epigenetic mechanism for the regulation of a variety of nor-
mal and disease-related processes, including cancers. Drugs 
affecting histone modifications have been already developed 
and showed promising results in the treatment for different 
tumor types (see Table 1 for more details).
Based on this knowledge, different types of histone 
deacetylase inhibitors, DNMT inhibitors, and small 
molecules that block enzymes that are implicated in these 
epigenetic mechanisms have been developed. In addition, 
combining conventional therapies to drugs that affect epi-
genetic mechanisms is becoming common. For example, 
clinical trials using a combination of DNMT inhibitors with 
conventional chemotherapy were well tolerated in cancer 
patients and showed encouraging results when compared 
with chemotherapy alone.42
Drugs targeting chromatin and nucleosome remodel-
ing proteins are also a promising therapeutic strategy to 
treat human cancers (Table 1). Some of these proteins Cancer Management and Research 2010:2 submit your manuscript | www.dovepress.com
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are deregulated in cancer, such as sirtuin 1 (SIRT1). It 
was recently shown that targeting this protein with drugs 
such as Salermide or Sirtinol can lead to the reactivation 
of pro-apoptotic genes that are epigenetically repressed 
exclusively in cancer cells.43 These drugs are also promis-
ing as an anticancer agent, providing molecular evidences 
that SIRT1 might be involved in human tumorigenesis.43 
Chromatin-remodeling proteins are important for proper 
gene expression, and new drugs targeting these proteins will 
be developed generating more effective therapies against 
cancer. All the epigenetic/epigenomic mechanisms and some 
of the drugs that have been tested for cancer therapies are 
represented in Figure 1.
The impact of new technologies  
on cancer research
Second-generation DNA sequencing technologies have been 
used to identify and detect genetic and genomic changes in 
tumors when compared with normal cells. In the epigenom-
ics field, these technologies have been helpful in identifying 
regions of the DNA that are differentially methylated and 
have different histone marks.44 The identification of proteins 
that are responsible for wrapping the nucleosome of tumor 
cells was also possible44 (see Table 2). The development of 
new technologies to study cancer epigenomes will be crucial 
for the identification of defects in tumor cells.
Thirty years ago, sodium bisulfite was first described as 
a reagent that could be used to detect DNA methylation in 
specific regions of the DNA.45 This discovery has revolu-
tionized the way we have been analyzing DNA methylation 
changes in cancer cells from different tumor types.45 This 
technology allowed the analyses of specific regions of the 
DNA, the so-called gene-by-gene analyses (Table 2), to evalu-
ate the percentages of DNA methylation and correlate it to 
gene expression. In addition to sodium bisulfite treatment, 
digestion with methylation-sensitive restriction enzymes and 
several different methods using restriction enzymes combined 
with polymerase chain reaction46 have been used for years. 
Some limitations of these methods include the low number 
of dinucleotide CGs or CpGs that can be analyzed at a time 
(Table 2). Analyses of individual genes and/or regions of 
the DNA may also be applied to evaluate histone marks and 
nucleosome packaging, with the use of antibodies against spe-
cific marks in the histone proteins. These procedures, however, 
Table 2 Different types of technologies to uncover epigenomic changes in cancer
Method(s) Description Examples References
Gene-by-gene 
analyses
Different methods that are used to evaluate methylation status of  
gene promoters. The most utilized technology is based in  
sodium bisulfite treatment that converts unmethylated citosines to  
uracil by deamination. Methylation changes are easily detected using  
this method after DNA sequencing. Other methods include digestion  
with MSRe and antibodies against methyl-binding proteins that  
can be used to detect specific methylation changes.
MSRE digestion, bisulfite 
sequencing, MSP, MethyLight, 
and others
45,46,88,89
ChiP-ChiP arrays Specific antibodies are used for proteins (ie, histones) that are 
binding to the DNA followed by array hybridization. Mainly used 
to identify regions that are active and/or inactive based on 
epigenetic modifications.
Chromatin immunoprecipitation 
combined with microarray 
hybridization
90
ChiP–Seq 
technology
Specific antibodies are used for proteins (ie, histones) that are binding  
to the DNA followed by DNA sequencing to map the locations of the  
histone proteins in the genome and their specific modifications. Second- 
generation DNA sequencing has been used to uncover these changes.
Chromatin immunoprecipitation 
combined with DNA sequencing
91
DNA 
methylation arrays
Different types of DNA methylation arrays have been used such 
as arrays containing CG-rich regions of the DNA. whole genome 
arrays are also generated after bisulfite conversion of the DNA.
CpG island specific arrays,  
whole genome bisulfite arrays
92,93
Second-generation 
DNA sequencing
Methodologies based on pyrosequencing and other technologies 
are allowing the generation of huge amounts of genomic and 
trascriptomic data. They have been also used to detect 
epigenomic modifications in human genomes.
Pyrosequencing, sequencing  
by oligo ligation and  
detection, sequencing  
by synthesis, and others
94,95
Third-generation 
DNA sequencing
This new generation comprises methodologies that will be available soon  
mainly based in nanotechnology (ie, nanopores and nanodetectors).  
These new methods have the potential to decrease the costs of  
sequencing a genome in a faster way than the current technologies.  
Applications for epigenomic analyses have been recently reported.
SMRT, nanosequencing,  
and others
47,48,96–99
Abbreviations: ChiP, chromatin immunoprecipitation; MSP, methylation-specific PCR; MSRE, methylation-sensitive restriction enzymes; SMRT, single molecule real time PCR.Cancer Management and Research 2010:2 submit your manuscript | www.dovepress.com
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are very laborious and restricted to the region(s) of interest. 
Recent methods were developed for epigenomic analyses, 
which can evaluate epigenetic changes on a global level in 
the genome of tumor cells (Table 2). Examples include chro-
matin immunoprecipitation combined with DNA sequencing 
(ChiP–Seq) and high-throughput DNA methylation analyses 
after sodium bisulfite treatment using new DNA sequencing 
technologies (Table 2). Second-generation DNA sequencing 
methods are mainly based on pyrosequencing and emulsion 
polymerase chain reaction combined with beads that are 
embedded in slides with small pores (for more information 
on second-generation DNA sequencing, see Table 2).
A wave of new sequencing technologies, named third-
generation DNA sequencing, have been developed with 
the promise of sequencing genomes, transcriptomes, and 
epigenomes faster and with lower costs. Some of these 
technologies are based on the so-called nanopores (Table 2). 
These pores are small holes that could be biological or solid, 
in which the DNA can pass and be detected in a controlled 
manner.47 These technologies rely on the detection of 
single molecules, and labeling of the sequencing substrate is 
sometimes required. It is possible that these new sequencers 
developed using nanotechnology could read long stretches of 
DNA in a greater or comparable way to the technologies that 
are currently available. A recent report has demonstrated that 
it is already possible to detect DNA methylation changes 
without the use of the reagent sodium bisulfite (which 
degrades the DNA and usually requires high amounts of 
starting material).48 This is possible in a single molecule real 
time sequencing reaction with nanodetectors.48 It is becoming 
clear that the new technologies under development will be 
of importance for research in epigenomics. This will have a 
positive impact on cancer research, facilitating the identifica-
tion of new biomarkers and drug targets.
Implications for cancer 
management
The stratification of patients based on their tumor profile and/
or specific biomarkers is becoming the best way to subgroup 
individuals with the same tumor characteristics. This field 
is also known as personalized or individualized medicine, 
and its objective is to associate the best treatment for each 
specific patient or group of patients. Personalized medicine 
involves the systematic use of molecular information about 
each individual patient to select or optimize preventative and 
therapeutic care. These new approaches are changing the way 
in which pharmaceutical companies try to identify and test 
new cancer drugs. The idea of a blockbuster drug that could 
treat a broad spectrum of tumor types has become unlikely; 
cancer is a complex disease, and even a specific cancer type, 
such as breast cancer, has a variety of subclasses with com-
pletely different pathological and molecular features.
Epigenomics is a unique approach to cancer research 
since it can help in the identification of groups of patients 
with the same epigenetic changes and characteristics in their 
tumors. The epigenetic drugs used today are unspecific and 
have side effects such as the ones that occur in conventional 
chemotherapy. This can vary from patient to patient, depend-
ing on the dosage that is prescribed. Importantly, lower dose 
treatments can reduce the side effects. The identification of 
DNA methylation and histone modifications associated with 
cancer may have important clinical utility in the future. The 
development of new technologies to uncover these changes 
in a high-throughput fashion will have a major impact as 
discussed above and shown in Tables 2 and 3.
Some advancement in the field of epigenetics and epig-
enomics has already led to the identification of specific bio-
markers to manage the disease (see Table 3 for more details). 
A variety of genes have been described as hypermethylated 
and/or hypomethylated in cancers, and this feature has shown 
some clinical significance in specific tumor types.49,50 Genes 
such as GSTP1, which is hypermethylated in a high percent-
age of prostate cancers, has been used as a biomarker for this 
disease in body fluids and biopsy specimens.51 In addition, 
groups of genes from the same pathway and/or network have 
shown the same epigenetic changes in tumors. Examples 
include genes implicated in cell adhesion, DNA repair, and 
apoptosis that can be downregulated by DNA methylation. 
Downregulation of genes associated with cell adhesion 
and migration can increase the risk of the tumor cells to 
metastasize to a secondary site in the body.52,53 For example, 
our group has already shown that the adhesion molecule 
ADAM23 is highly methylated in breast tumors, and this 
feature is correlated to metastases and a poor prognosis in 
breast tumors.54,55 A classic example of a DNA repair gene 
downregulated by DNA methylation is the MGMT gene, 
which is silenced by epigenetic mechanisms in brain tumors.56 
Tumors that do not express the gene MGMT are more sensi-
tive to radiotherapy and chemotherapy with temozolomide, 
and this molecular feature has been used in clinical decisions 
and disease management for glioblastomas.56,57 Changes in 
the profile of histone modifications have also been used to 
evaluate and manage the risk of prostate cancer recurrence 
in patients.58
Another group of genes in which epigenetic changes can 
be monitored to manage cancer risk and progression is the Cancer Management and Research 2010:2 submit your manuscript | www.dovepress.com
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microRNA (miR) gene family.59 Some studies have already 
shown that miRs can be regulated by epigenetic mechanisms 
(Table 3). Changes in DNA methylation have been reported 
in specific cancer types for different miRs.60 Additionally, 
miRs are associated with important embryonic gene pathways 
in cancer, and this connection between embryonic develop-
ment and cancer should be carefully examined for drug 
development in the future.61 Since miRs regulate hundreds 
to thousands of protein-coding genes by incomplete base-
pairing,62–64 allowing them to affect networks and pathways 
of genes, it will be of importance to monitor miR expression 
changes mediated by epigenetics during cancer initiation 
and progression.
In the case of drug development and new therapies, it 
is likely that the future of epigenetic therapy will include 
the use of multiple drugs that individually have little effect 
in epigenetic silencing but that might be expected to have 
synergistic and/or additional effects when combined. For 
example, a recent study using histone deacetylase inhibitors 
and high-dose chemotherapy both in vitro and in vivo indi-
cated that this combination might overcome chemoresistance, 
achieve durable remission, and improve survival of patients 
with Burkitt lymphoma.65 A major problem with the use of 
current epigenetic drugs is that they are nonspecific and can 
reactivate genes randomly. A concern is that they can cause 
a whole-genome hypomethylation, increase the number of 
chromosomal abnormalities, and affect the tumorigenic phe-
notype of cancer cells as previously described.66,67 However, 
evidence that DNA methylation inhibitors act only in dividing 
cells, leaving nondividing cells unaffected, has already been 
reported.68 In addition, it seems that these drugs activate genes 
that have become abnormally silenced in cancer.69,70
The question we face today in the epigenomics field 
applied to cancer research is ‘How to manage cancer with 
the new technologies and tools that are becoming available?’ 
The new technologies under development will facilitate 
the identification of better epigenetic markers and may 
aid in the development of more specific therapies. These 
drugs will be focused in a group of genes and not the 
entire epigenome (see Table 1 for epigenetic drugs). The 
other question is ‘What will be the impact of epigenomics 
in the clinics?’ In other words, how could we translate the 
discoveries from basic science to the patient’s bedside? In 
this regard, the FDA has already approved a few epigenetic 
Table 3 Some examples of epigenetic and epigenomic changes in single genes or group of genes and their potential impact in cancer 
management
Gene(s) Epigenetic/epigenomic changes Impact for cancer management References
GSTP1 Hypermethylated in 80%–90% of 
prostate cancers and unmethylated 
in benign hyperplasic tissue.
Detection of hypermethylated GSTP1 could  
help to distinguish normal prostate cells  
from cancer cells. it could also be used as a  
biomarker in body fluids and biopsy specimens.
51
P16ink4A One of the most common tumor suppressors 
inactivated by DNA methylation in tumors. 
Hypermethylation has been linked to poor 
outcome in different types of cancer.
p16ink4A could be used as 
prognostic marker in cancer.
100
Apoptosis and cell 
cycle genes (ie, DAPK, 
p73, and others)
Hypermethylation has been linked to  
poor outcome in different types of cancer.
Genes associated to apoptosis that are  
hypermethylated in cancers could be  
used as prognostic markers.
101–103
Adhesion molecules  
(ie, cadherins, ADAM23,  
ADAM33, and others)
Hypermethylated in different types of  
cancer and associated with cancer metastasis.
Genes associated to cell adhesion 
could be used as markers for 
disease progression.
52–55,104
DNA repair genes 
(ie, MGMT, hMLH1, 
BRCA1, and others)
Hypermethylation of genes implicated  
in DNA repair could help in identifying tumors  
that are more susceptible to therapies such as  
radiotherapy helping in personalized treatment.
The use of individualized therapies 
could aid in patient outcome.
56,57,105
Histones Differential histone modifications such  
as acetylation and methylation are associated  
to cancer recurrence and a worse prognosis.
The identification of patients that are at  
more risk of recurrence of the disease could  
help in decisions related to treatment and  
a better follow-up into the clinic.
58
miRNAs DNA methylation and histone 
modifications of miRNA genes has 
been reported by different groups.
miRNAs are noncoding genes that can regulate  
several proteins in a cellular network and/or pathway.  
Reexpression of miRNAs in tumors may have an  
impact for the regulation of key genes in the cells.
60,70,106
Abbreviations: ADAM23, a desintegrin and metalloprotease domain 23; ADAM33, a desintegrin and metalloprotease domain 33; BRCA1, breast cancer gene 1; DAPK, Death-
associated protein kinase; GSTP1, glutathione S-transferase P1; hMLH1, human mutL homolog 1; MGMT, O6-methylguanine-DNA methyltransferase; miRNAs, microRNAs.Cancer Management and Research 2010:2 submit your manuscript | www.dovepress.com
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drugs for different tumor types, and some of these are very 
promising (Table 1 and Figure 1). Molecular biomarkers, 
such as genes or groups of genes with changes in epigenetic 
modifications in tumors, have also been used to guide clini-
cal decisions. Examples are epigenetic changes in GSTP1 
in prostate cancer, p16ink4A in different types of cancer, 
and MGMT in brain tumors (see Table 3). There are com-
panies (ie, Oncomethylome Sciences, Epigenomics AG, 
Sequenom, and others) already offering a test with a panel 
of epigenetic markers covering different genomic regions 
for cancers (see Table 4 for more details). More recently, 
the company Exact Sciences released a combined test for 
four methylation markers for early detection of colon cancer 
with a 100% sensitivity. The advantages of using epigenetic 
markers for early detection of cancer and disease monitoring 
is that the test can be done in a small tumor sample or even 
in body fluids such as stool, blood, spinal fluid, and urine. 
Depending on the combination of markers obtained after 
the tests, clinicians are able to predict the appearance of 
the disease and also group cancer patients based in tumor 
aggressiveness and other clinical features, facilitating clini-
cal decisions. Clearly, the impact of epigenomics in cancer 
management is expected to increase with the advent and 
development of new technologies.
Conclusions and future directions
In conclusion, the burgeoning fields of genomics and 
epigenomics comprise essential facets of modern cancer 
research. The FDA has already approved some epigenetic 
drugs, and others are in clinical trials and under develop-
ment, demonstrating that this field already affects the way 
we manage cancer. In addition, single genes and groups of 
genes from the same pathway have been identified as dif-
ferentially methylated in cancers, and some have been used 
as molecular biomarkers in order to identify patients with a 
better or a worse prognosis. Histone modification changes 
have also been used as markers to monitor cancer patients. 
Clearly, epigenetic changes in tumors will affect the decisions 
that are made in the clinics for the patients, especially treat-
ment regimens and disease progression monitoring. Future 
directions include the discovery of new biomarkers and the 
development of more efficient drugs against different tumor 
types with the evolving technologies and the emergence of a 
new generation of DNA sequencers. Based on the informa-
tion discussed here, growing evidence indicates that new 
epigenomic tools will increasingly affect the way we monitor 
and manage cancer in the future.
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Table 4 examples of companies offering predictive epigenetic-based tests for cancer diagnosis and monitoring
Company Epigenetic test(s) Impact for clinical decisions Website
Oncomethylome 
sciences
MGMT methylation 
analysis
This test indicates if patients with unmethylated (functioning)  
MGMT will benefit from the addition of  
temozolomide to the standard treatment of radiation therapy.  
Patients with methylated (silenced) MGMT  
have longer progression-free and overall survivals with the  
combination of radiation therapy and temozolomide. This company  
also tests other genes for different tumor types in body fluids.
www.oncomethylome.com
epigenomics AG OncoSign and epi 
proColon
Biomarker candidates are used to identify drug response  
in cancer patients based in the DNA methylation analyses  
of a set of genes. Other epigenetic tests are also offered  
for colon cancer management facilitating clinical decisions.
www.epigenomics.com
Sequenom Cancer epiPanels The Cancer epiPanel contains targets of more than 400 cancer- 
related genes. it includes prevalidated assays covering over 12,000 CpG  
sites in promoter regions of genes known to be involved in neoplastic  
transformation. The Cancer epiPanel can be used to produce  
quantitative DNA methylation profiles helping in tumor classification.
www.sequenom.com
exact sciences Stool-based DNA 
methylation analyses
The company offers noninvasive, molecular screening technologies  
for the early detection of colorectal cancer using a combination  
of DNA methylation markers. Stool-based DNA technology  
is used for disease management.
www.exactsciences.comCancer Management and Research 2010:2 submit your manuscript | www.dovepress.com
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